RYTM

SEC source: 0001649904-26-000026 · form4.xml · derivative · entry 7

Meeker David P · CIK 0001385155 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,431

Underlying: Common Stock · 50,000 shares

Expires 2027-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock options were granted on February 8, 2017 and vested and became exercisable in three equal annual installments measured from January 6, 2017.

SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 6

Meeker David P · CIK 0001385155 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 239,258

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.

F7 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.00 to $105.31 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 5

Meeker David P · CIK 0001385155 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 241,558

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.97 to $104.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 4

Meeker David P · CIK 0001385155 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 243,375

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.97 to $103.96 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 3

Meeker David P · CIK 0001385155 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 252,073

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.96 to $102.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 2

Meeker David P · CIK 0001385155 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 282,819

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.96 to $101.95 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 1

Meeker David P · CIK 0001385155 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 289,258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.

F2 · balance_after: Includes 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on 2-28-2026.

SEC source: 0001649904-26-000023 · form4.xml · derivative · entry 5

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,813

Underlying: Common Stock · 57,187 shares

Expires 2028-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.

F5 · derivative.exercise_date: This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments.

SEC source: 0001649904-26-000023 · form4.xml · nonDerivative · entry 4

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,024

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000023 · form4.xml · nonDerivative · entry 3

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 142,212

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000023 · form4.xml · nonDerivative · entry 2

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,726

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000023 · form4.xml · nonDerivative · entry 1

Smith Hunter C · CIK 0001636385 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 176,798

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.

SEC source: 0001649904-26-000020 · form4.xml · derivative · entry 2

Joshi Manher · CIK 0001978048 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F2 · derivative.exercise_date: The Restricted Stock Units vest as to 25% of the Restricted Stock Units on September 1 of each of 2027, 2028, 2029, and 2030, such that the Restricted Stock Units shall be fully vested on September 1, 2030, subject to the Reporting Person continuing in service through each such vesting date.

F3 · derivative.expiration_date: The restricted stock units have no expiration date.

SEC source: 0001649904-26-000020 · form4.xml · derivative · entry 1

Joshi Manher · CIK 0001978048 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-08-16

F1 · derivative.exercise_date: The Stock Options vest and become exercisable as to 25% of the total number of shares subject to the option on the first anniversary of the grant date and as to 6.25% of the total number of shares subject to the option upon the Reporting Person's completion of each successive three months of service to the Corporation.

SEC source: 0001649904-26-000009 · form4.xml · derivative · entry 5

Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,601 shares

Expires 2032-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.

F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

SEC source: 0001649904-26-000009 · form4.xml · derivative · entry 4

Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,283

Underlying: Common Stock · 35,000 shares

Expires 2030-11-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.

F2 · derivative.exercise_date: The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.

SEC source: 0001649904-26-000009 · form4.xml · nonDerivative · entry 3

Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.

SEC source: 0001649904-26-000009 · form4.xml · nonDerivative · entry 2

Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,834

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.

SEC source: 0001649904-26-000009 · form4.xml · nonDerivative · entry 1

Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,233

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.

SEC source: 0001649904-26-000013 · form4.xml · nonDerivative · entry 4

Garfield Alastair · CIK 0002027261 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,295

F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $118.73 to $119.52 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000013 · form4.xml · nonDerivative · entry 3

Garfield Alastair · CIK 0002027261 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,095

F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $117.73 to $118.71 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000013 · form4.xml · nonDerivative · entry 2

Garfield Alastair · CIK 0002027261 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,495

F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.72 to $117.66 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000013 · form4.xml · nonDerivative · entry 1

Garfield Alastair · CIK 0002027261 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,051

F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.67 to $116.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000015 · form4.xml · derivative · entry 3

Shulman Joseph · CIK 0001909855 · Chief Technical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,945

Underlying: Common Stock · 2,024 shares

Expires 2032-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.

F2 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

SEC source: 0001649904-26-000015 · form4.xml · nonDerivative · entry 2

Shulman Joseph · CIK 0001909855 · Chief Technical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,915

F1 · kind: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.

SEC source: 0001649904-26-000015 · form4.xml · nonDerivative · entry 1

Shulman Joseph · CIK 0001909855 · Chief Technical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.

SEC source: 0001649904-26-000007 · form4.xml · derivative · entry 8

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,875

Underlying: Common Stock · 46,625 shares

Expires 2032-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.

F8 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

SEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 7

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,655

F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.01 to $117.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 6

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,974

F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.01 to $117.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 5

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,182

F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.01 to $116.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 4

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,750

F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $114.01 to $115.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 3

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,355

F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $112.84 to $112.92 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 2

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,355

F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $111.58 to $112.30 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 1

Mazabraud Yann · CIK 0001774702 · EVP, Head of International

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,655

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.

SEC source: 0001104659-26-080397 · tm2619643-1_4seq1.xml · derivative · entry 3

Garfield Alastair · CIK 0002027261 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,888

Underlying: Common Stock · 4,445 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.

F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.

SEC source: 0001104659-26-080397 · tm2619643-1_4seq1.xml · nonDerivative · entry 2

Garfield Alastair · CIK 0002027261 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,058

F2 · kind: These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein.

SEC source: 0001104659-26-080397 · tm2619643-1_4seq1.xml · nonDerivative · entry 1

Garfield Alastair · CIK 0002027261 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

SEC source: 0001104659-26-077862 · tm2619022-1_4seq1.xml · derivative · entry 4

GOOD JENNIFER L · CIK 0001229245 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,324

Underlying: Common Stock · 2,324 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

SEC source: 0001104659-26-077862 · tm2619022-1_4seq1.xml · derivative · entry 3

GOOD JENNIFER L · CIK 0001229245 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,691

Underlying: Common Stock · 3,691 shares

Expires 2036-06-23

F3 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001104659-26-077866 · tm2619022-4_4seq1.xml · derivative · entry 4

MCGIRR DAVID W J · CIK 0001219023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,324

Underlying: Common Stock · 2,324 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

SEC source: 0001104659-26-077866 · tm2619022-4_4seq1.xml · derivative · entry 3

MCGIRR DAVID W J · CIK 0001219023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,691

Underlying: Common Stock · 3,691 shares

Expires 2036-06-23

F3 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001104659-26-077867 · tm2619022-5_4seq1.xml · derivative · entry 4

JEAN CHRISTOPHE · CIK 0001378435 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,324

Underlying: Common Stock · 2,324 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

SEC source: 0001104659-26-077867 · tm2619022-5_4seq1.xml · derivative · entry 3

JEAN CHRISTOPHE · CIK 0001378435 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,691

Underlying: Common Stock · 3,691 shares

Expires 2036-06-23

F3 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001104659-26-077863 · tm2619022-2_4seq1.xml · derivative · entry 4

Arbuckle Stuart A · CIK 0001557290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,324

Underlying: Common Stock · 2,324 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

SEC source: 0001104659-26-077863 · tm2619022-2_4seq1.xml · derivative · entry 3

Arbuckle Stuart A · CIK 0001557290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,691

Underlying: Common Stock · 3,691 shares

Expires 2036-06-23

F3 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001104659-26-077864 · tm2619022-3_4seq1.xml · derivative · entry 4

TETRAULT LYNN A. · CIK 0001645512 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,324

Underlying: Common Stock · 2,324 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F4 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

F4 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

SEC source: 0001104659-26-077864 · tm2619022-3_4seq1.xml · derivative · entry 3

TETRAULT LYNN A. · CIK 0001645512 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,691

Underlying: Common Stock · 3,691 shares

Expires 2036-06-23

F3 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001104659-26-077862 · tm2619022-1_4seq1.xml · derivative · entry 2

GOOD JENNIFER L · CIK 0001229245 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,712 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units are fully vested. The restricted stock units have no expiration date.

F2 · derivative.expiration_date: The restricted stock units are fully vested. The restricted stock units have no expiration date.

SEC source: 0001104659-26-077862 · tm2619022-1_4seq1.xml · nonDerivative · entry 1

GOOD JENNIFER L · CIK 0001229245 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,712

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

SEC source: 0001104659-26-077866 · tm2619022-4_4seq1.xml · derivative · entry 2

MCGIRR DAVID W J · CIK 0001219023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,712 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: The restricted stock units are fully vested. The restricted stock units have no expiration date.

F2 · derivative.expiration_date: The restricted stock units are fully vested. The restricted stock units have no expiration date.